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Background: Surgical site infections (SSI) after vascular surgery are related to 
substantial morbidity. Restriction of bacterial access to the site of surgery with 
cyanoacrylate sealant is a new concept. We performed a randomized clinical trial to 
assess the effect of the sealing of skin with a cyanoacrylate at the site of surgery on 
the incidence of SSI’s after arterial reconstruction.
Methods: Patients scheduled for vascular reconstruction in or distal to the groin 
were randomized into a treatment and control group. Standard measures for 
preventing contamination of the surgical field were taken in the control group, 
whereas cyanoacrylate was used as a skin sealant at the surgical site in the patients 
in the treatment group. We hypothesized that the incidence of SSI with the use of 
cyanoacrylate would be two-thirds (67%) lower than that with standard preparation 
of the surgical site, and performed an interim analysis of 50 patients to assess this.
Results: Risk factors among the 50 patients in the study included smoking (28%), 
hypertension (77%), diabetes mellitus (36%), and hypercholesterolemia (74%). 
Indications for surgery were invalidating claudication (Fontaine IIb), pain at rest 
or tissue necrosis. The overall SSI-incidence was 3/47 (6%), without differences 
between groups; 9% SSIs in the control group versus 4% SSIs in the intervention 
group.
Conclusion: We could not confirm a reduction in the incidence of SSI after inguinal 
vascular surgery with the use of a cyanoacrylate skin sealant as compared with 
conventional means for preparing the surgical site.
Introduction
The incidence of surgical site infections (SSI’s) shows wide variation, depending 
on patient-, surgeon- and hospital-related factors. In inguinal vascular procedures, 
incidences of SSI of 7% - 44% have been described (1, 2). Although surgical 
techniques have evolved considerably in recent decades, the incidence of SSI after 
vascular surgery, and its consequences, have not changed. In this context, groin 
infection in relation to the infection of prosthetic grafts in vascular surgery (3, 4) is 
responsible for a high rate of limb-loss and death(5).
Possible reasons for the relatively high incidence of infections in the groin in relation 
to the use of prosthetic vascular grafting to the femoral artery include the close 
proximity of the groin to the perineum, the relatively superficial position of these 
grafts, and the presence of lymphatic tissue ventral to the common femoral artery 
(6). More than 50% of all SSIs are caused by endogenous bacteria (7). The 
elimination of these micro-organisms could reduce the risk of groin infection after 
vascular surgery. A recent review and cost analysis found that replacement of iodine 
antisepsis by antisepsis with chlorhexidin was associated with statistically 
significantly fewer SSI (adjusted risk ratio 0.64, 95% confidence interval [CI] 
0.51-0.80)(8). However, the use of iodine draping did not cause a significant 
decrease in the incidence of SSIs (risk ratio 1.03, 95% CI 0.064-1.66)(9).
Cyanoacrylate sealant is a film-forming liquid provided in a ready-to-use applicator 
that has been developed to bond to the skin surface. Cyanoacrylate was cleared in 
September 2006 (by the European Medicines Agency, London, United Kingdom) as 
a surgical drape accessory; it bonds to the skin upon application and immobilizes 
the bacteria that survive the application of antimicrobial products for surgical 
preparation of the patient’s skin. The cyanoacrylate remains on the skin after the 
completion of the surgical procedure and may prevent contamination of the surgical 
incision during the first few days post-operatively. Dohmen et al. studied the effect of 
cyanoacrylate on the incidence of SSI after coronary artery bypass grafting (CABG)
(10). They found that superficial or deep sternal SSI developed in seven patients 
(7.8%) in a control group (n= 545) as compared with only one patient (1.1%) in 
a group (n= 131) whose surgical site was applied with cyanoacrylate (OR 7.5, 
p=0.062). Iyer et al. recently reported a significant reduction of SSI in the 
harvesting of portions of the greater saphenous vein when using a 
cyanoacrylate-based microbial sealant (11). Only one SSI occurred (2.1%) in the 
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group treated with sealant, whereas the incidence of SSI in the control group was 
25.5% (n=12, p=0.001).
In the present study we tested the hypothesis that the additional attention given to 
the specific issue of SSI in a clinical study of its occurrence and the use of a 
cyanoacrylate skin sealant at the site of surgery could more than halve the 
incidence of SSI in the groin region after vascular procedures, as compared with 
standard preventive measures. The study and the present report were done 




We conducted a randomized, single-blind, clinical trial to evaluate the effect of a 
cyanoacrylate sealant on the incidence of groin infections after vascular surgery on 
the femoral artery. In the treatment arm of the trial a ready-to-use applicator 
(InteguSeal® IS200, Kimberly-Clark, Roswell, GA) was used to apply the sealant to 
the incision site. Wounds were evaluated with the Southampton Wound 
Assessment-score (SWA-score) (13). In case of fluid evacuation from the wound 
bacterial cultures were taken. 
During a pre-operative outpatient clinical visit, all consecutive adults over 18 y of 
age who had an indication for infrainguinal vascular reconstruction were informed 
about the study, and written informed consent was obtained from those who agreed 
to participate. The surgical procedures done on the patients in the study included 
common femoral reconstruction, femoro-popliteal, femoro-crural, and femoro-
femoral crossover bypass graft implantation; excluded were thrombectomies done 
through an inguinal incision, patients younger than 18 y of age, and those with a 
previous groin incision or vascular reconstruction done cranially to the site of 
incision in the present study (e.g., endovascular aneurysm repair procedures). After 
signing an informed consent agreement, patients were randomly assigned in a 1:1 
ratio to one of the two groups, with randomization accomplished by the drawing of a 
sealed envelope in the operation room one-half hour before surgery by the surgeon 
performing the operation. Ethical approval for the study was granted by the 
Committee on Research involving Human Subjects, Arnhem-Nijmegen, The 
Netherlands (reference NL25592.091.08).
Procedure
All patients received prophylactic cephazolin (Kefzol®, Lilly, Houten, The 
Netherlands) 2 g IV prophylactically from 15-60 min before the incision for surgery 
was made. Patients were prepared in the routine manner for surgery, involving 
removal of hair with a clipper immediately before the procedure, disinfection with 
chlorhexidine 0.5% in 70% isopropyl alcohol, and sterile draping with disposable 
drapes (Secu-Drape®, Sengewald, Germany). In the treatment group cyanoacry-
late was applied to the site of surgical incision after regular disinfection but before 
incision, by pressing the foam tip of the applicator gently against the skin (Fig. 1). All 
patients underwent a wound evaluation at 2 d, 
14 d, and 6 wk after operation. The wound evaluation was done at 2 wk and 6 wk 
post-operatively by a researcher who was blinded to the randomization done in the 
study, using the Southampton Wound Assessment (SWA) score (13) and 
maximizing correct definition through the additional use of wound culture results. 
A blinded wound evaluation at 2 d post-operatively was not possible. If a patient 
presented with a wound infection before the next scheduled wound evaluation, the 
infection was registered under the most recent previous evaluation. An efficacy 
interim analysis of the data was planned after inclusion of the first 50 patients.
Outcome measures
The primary endpoint was the incidence of SSI within the first two postoperative 
weeks, defined as a SWA score of grade III or higher, in combination with a positive 
fluid result of culture of a fluid specimen obtained aseptically from a primarily closed 
surgical site (14). Criteria for SWA scores are given in Table 1 (13). 
Fig. 1. The ready-to-use applicator for cyanoacrylate sealant in the groin of a patient.
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Sample size calculation
The mean incidence of vascular SSI as reported in the literature is 12% (1, 2, 6, 14, 
15). The assumption had been made that the use of a cyanoacrylate sealant would 
reduce the incidence of SSI by two-thirds of this reported value, from 12% to 4% 
(10, 11), as compared with standard preventive measures. For a trial demonstrating 
a superiority of cyanoaclylate with an effect size of 90% and a margin of 10%, 180 
patients per group were needed (alpha 5%, power 80%) to provide a significant 
difference, as calculated in a power analysis. We performed a power analysis with 
the following formula (16): n = 8 x (P1(1 – P1) + P2(1 – P2))/(P1 – P2)2, on the 
basis of an intention-to-treat principle. Significance was tested with the Fisher Exact 
test. A value of p< 0.05 was considered significant.
 Results
The study included 50 patients and was conducted from January 2010 to April 2011 
at the Wilhelmina Hospital, Assen, The Netherlands. All patients approved their 
participation in the study. Three patients were excluded from analysis of the study 
Clinical description
Grade 0 Normal wound healing




Grade II Erythema plus other signs of inflammation
A At one point
B Around sutures
C Along the wound
D Around the wound
Grade III Clear or haemoserous discharge
A At one point only (< 2cm)
B Along the wound (> 2cm)
C Large volume
D Prolonged (> 3d)
Grade IV Pus
A At one point only (< 2cm)
B Along the wound (> 2cm)
Table 1. Southampton wound assessment
data because of early post-operative death. Two of these three patients died from 
cardiac complications in the immediate postoperative period and the third died from 
bowel ischemia one week after vascular reconstruction in the groin (Fig. 2). As a 
result, a total of 47 groin incisions were available for analyses.
Figure 2. Details of the screening and randomization procedures used in the study.
Patients included in the analyses had a mean age of 71+10 y, and 28 patients were 
male (60%). Co-morbidity included a history of smoking in 28% (n= 13) of the 
patients, hypertension in 74% (n= 36), diabetes mellitus in 36% (n= 17), and 
hypercholesterolemia in 72% (n= 34). In 68% (n= 32) only a vascular reconstruction 
of the common femoral artery and its branches was performed. The remaining 
operations included 10 femoro-popliteal bypass procedures, one femoro-tibial 
bypass, two femoro-femoral cross-overs, and two endarteriectomies of the common 
femoral artery in combination with a percutaneous transluminal angioplasty (PTA) of 
the superficial femoral artery. The group in which the cyanoacrylate was used and 
the group given standard surgical preparation were comparable with regard to the 
types of procedures and risk factors in each group (Table 2). 
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The overall incidence of SSI’s was 6% (3 patients)(Table 3). At all measured time 
points, the difference in incidence of SSI in the treatment and control groups was 
smaller than expected (in the control group, two infections were diagnosed, on 
post-operative days 6 and 18, respectively, and in the treatment group, one infection 





Gender (male) 14 (64%) 14 (56%)
Smoking 7 (32%) 6 (24%)
Hypertension 19 (86%) 17 (68%)
Dyslipidemia 17 (77%) 17 (68%)
Diabetes mellitus 9 (41%) 8 (32%)
BMI (SD) 27 (4.6) 28 (4.5)
Age
   < 50 y 1 (5%) 1 (4%)
   51-60 y 2 (9%) 5 (2%)
   61-70 y 7 (32%) 9 (36%)
   71-80 y 7 (32%) 4 (16%)
   > 80 y 5 (23%) 6 (24%)
Fontaine IIa 4 2
Fontaine IIb 9 12
Fontaine III 6 8
Fontaine IV 3 3
Common femoral reconstr. 16 (73%) 16 (64%)
Femoro-popliteal bypass 3 (14%) 7 (28%)
Femoro-crural bypass 1 (5%) 0
Crossover bypass 0 2 (8%)
Other 2 (9%) 0
Mean operating time, min (SD) 132 (41.4) 151 (48.0)
Table 2. Procedures and risk factors in study groups. BMI= body mass index; CA= cyanoacrylate.
No SSI SSI
Cyanoacrylate (-) 20 (91%) 2 (9%)
Cyanoacrylate (+) 24 (96%) 1 (4%)
Table 3. Number of SSIs in study groups. SSI= surgical site infection
The two infections in the control group were caused by Staphylococcus aureus and 
Pseudomonas aeruginosa. The patient with SSI in the group treated with 
cyanoacrylate, took a bit longer to develop symptoms and had only Staphylococcus 
aureus in its culture.
The two patients in the control group who developed infections underwent 
endarterectomy of the common femoral artery with venous patching. They were 
empirically treated with oral antibiotics (amoxicillin/clavulanic acid 625mg 3dd), and 
their wounds were opened and rinsed with water twice a day until closure. Both 
healed without further complications. A re-operation at 22 days after initial surgery 
was required in the patient in the cyanoacrylate group who developed a SSI 
because of an infected polytetrafluoroethylene femoro-femoral crossover bypass.
Figure 3. Kaplan-Meier curve of 25 patients treated with cyanoacrylate skin sealant before surgery 
(treatment group) and 22 patients prepared for surgery without cyanoacrylate (control group).
Lymphatic complications occurred in two patients each, in the cyanoacrylate and 
control group. All of these patients had sterile fluid draining from their surgical 
incisions, as confirmed by negative cultures in all four cases.
Discussion
the results of the present study. Various factors may explain the difference. First, 
the study conducted by Dohmen et al. had a selection bias (10). Patients treated 
with the cyanoacrylate sealant in their study underwent surgery by one surgeon, 
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whereas other surgeons treated patients in the control group. Second, the 
operations done both by Iyer et al. and done by Dohmen et al. (10, 11) were 
performed in clean areas of the body, whereas the groin is usually considered to be 
clean-contaminated. A higher overall incidence of SSI could therefore have been 
expected. The skin of the groin is known to contain more sweat glands, and 
develops folds in a seated patient, thereby creating an environment for microbial 
contamination (19). Moreover, these folds increase the flexibility of the skin in the 
groin, thereby causing multiple cracks to develop in the sealant and counteracting 
its mechanism of action. A recent trial confirmed our conclusion in showing no 
significant decline in the incidence of SSI in 496 incisions treated with the same 
cyanoacrylate as used in our study (18). A better surgical site for research on the 
use of cyanoacrylate would be the area of the carotid artery, but because SSI in this 
area is rare, larger study groups would be needed to provide statistical power in a 
comparison of cyanoacrylate with other preparative techniques for carotid surgery. 
The present study has several limitations. First, the study was a randomized, single 
site trial, and may therefore have been susceptible for patient selection. Second, the 
preponderance in the study of non-smokers and patients without CLI was 
surprisingly high (72% and 87%, respectively), which may well have affected the 
incidence of SSIs. Unfortunately, screening for colonization with S. aureus was not 
performed pre-operatively. All cultures of the infected incisions contained S. aureus, 
and they could possibly could have been prevented had preoperative eradication 
been performed (20). Additionally, most of the surgical procedures done in the study 
consisted solely of a reconstruction of the common femoral artery, and the 
performing surgeon was informed about the allocation of the patient, thereby 
creating the risk of bias in the conduct of the surgeon. All of the foregoing factors 
may have attributed to the relatively low incidence of infections in the present study.
In conclusion, we could not show a reduction in the incidence of SSI in the groin 
after vascular surgery following the use of cyanoacrylate skin sealant. The number 
of patients needed to treat to reach clinical significance was considered too great for 
clinical relevance of the findings in the present study. A multi-center trial, preferably 
including older patients with CLI, might show significance with a lower 
number-needed-to-treat of patient for such a finding.
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